Earnings Call · Q4 FY2025·2026-02-12

Q4 25EPS -10.26%·Rev n/aQ3 25EPS -49.59%·Rev n/aQ2 25EPS +11.36%·Rev n/aQ1 25EPS +4.27%·Rev n/a⚠ consensus missing

Ultragenyx Pharmaceutical Inc. RARE

Joshua Higa — Vice President of Investor Relations

Emil Kakkis — Chief Executive Officer and President

Howard Horn — Chief Financial Officer

Erik Harris — Chief Commercial Officer

Eric Crombez — Unknown

+8.3%1d on move date+8.1% vs SPY3d+6.9%5d−0.1%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RARE calls or request research access.

More RARE calls Browse calls Request research access